Stock Screener App

Gratuito -

Installare

0.7033

0.00% 0.00

Skye Bioscience Inc (SKYE)

Panoramica Notizia Cronologia dei prezzi Forum Previsione

Skye Bioscience Inc Borsa (SKYE) Ultime notizie

Bronstein, Gewirtz & Grossman, LLC Encourages Skye Bioscience, In - The National Law Review

Skye Bioscience, Inc. Financial Disclosures & SEC Filings - TradingView

Price to earnings forward of Skye Bioscience, Inc. – NASDAQ:SKYE - TradingView

Enterprise value to revenue forward of Skye Bioscience, Inc. – NASDAQ:SKYE - TradingView

Price to book forward of Skye Bioscience, Inc. – NASDAQ:SKYE - TradingView

Enterprise value to EBIT forward of Skye Bioscience, Inc. – NASDAQ:SKYE - TradingView

Price to sales forward of Skye Bioscience, Inc. – NASDAQ:SKYE - TradingView

Skye Bioscience, Inc. Actuals & Estimates (NASDAQ:SKYE) - TradingView

Skye Bioscience, Inc. Actuals & Estimates (FWB:09R) - TradingView

SKYE Forecast — Price Target — Prediction for 2027 - TradingView

Skye Bioscience Moves Listing to Nasdaq Capital Market - The Globe and Mail

Skye Bioscience to Move Listing to Nasdaq Capital Market After Equity Shortfall - TradingView

Skye Bioscience (NASDAQ: SKYE) shifts to Nasdaq Capital Market amid listing notices - Stock Titan

Skye Bioscience Inc (SKYE) Financial Health: Profitability & Balance Sheet Analysis - TradingKey

Skye Bioscience Inc (SKYE) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey

Skye Bioscience, Inc. Stock 12‑Month Price Target Cut to $7.33, Implies 937% Upside - TradingView

Skye Bioscience Inc (SKYE) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey

Skye Bioscience Inc (SKYE) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey

Skye Bioscience Inc (SKYE) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey

Skye Bioscience Inc (SKYE) Valuation: PE, PB & Fair Value Analysis - TradingKey

Skye Bioscience Inc (SKYE) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey

Skye Bioscience Inc (SKYE) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey

Skye Bioscience Inc (SKYE) Institutional Confidence - TradingKey

Piper Sandler Maintains SKYE BIOSCIENCE INC(SKYE.US) With Buy Rating, Cuts Target Price to $6 - 富途牛牛

SKYE News | SKYE BIOSCIENCE INC (NASDAQ:SKYE) - ChartMill

Skye Bioscience (SKYE) Surges 5% as Key Support Holds, Resistance in FocusPut Wall - newsline.com

SKYE Q1 2026 Earnings: EPS Misses Estimates as Pre-Revenue Biotech Advances Pipeline, Stock RisesEBITDA Margin Trends - newsline.com

SKYE Stock Chart | SKYE BIOSCIENCE INC (NASDAQ:SKYE) - ChartMill

Skye Bioscience (SKYE) Holds Near Support Amid Modest GainsDividend ETF - newsline.com

Skye Bioscience, Inc. Amends Articles of Incorporation to Increase Authorized Shares – SEC 8-K Filing May 2026 - Minichart

SKYESkye Bioscience Inc Latest SEC Filings - Finviz

Skye Bioscience Expands Authorized Shares After Shareholder Approval - TipRanks

Skye Bioscience (NASDAQ: SKYE) holders back major share authorization increase - Stock Titan

Skye Bioscience (SKYE) Tumbles 8.8% as Selling Pressure Intensifies, Support in SightFactor Rotation - The Legal Advocate

SKYE Stock Quote Price and Forecast - CNN

Skye Bioscience (SKYE) Edges Higher, Testing Resistance Near Key LevelsUpthrust Pattern - The Legal Advocate

Skye Bioscience (SKYE) Edges Higher Amid Renewed Buyer InterestNarrow Range Breakout - The Legal Advocate

Skye Bioscience (SKYE) Holds Above Support After Modest GainTrading Ideas - newsline.com

SKYE Q1 2026 Earnings: EPS Misses Estimates Amid No Revenue, Shares Edge HigherReturn On Assets - The Legal Advocate

Skye Bioscience (SKYE) Edges Higher as Support Holds, Testing Key Resistance at $0.88Volume Oscillator - The Legal Advocate

SKYE: All proposals passed, directors elected, and no stakeholder questions were raised - TradingView

SKYE Q1 2026 Earnings: EPS Slightly Below Estimates, Stock Surges 16% on Strategic ProgressMargin Guidance - The Legal Advocate

Skye Bioscience Rallies; Holiday Week Puts Focus on Tuesday - Bez Kabli

Skye Bioscience Surges 7.7%: Biotech Stock Tests Resistance at $0.81IV Percentile - newsline.com

Skye Bioscience gets approval to open second cohort in study By Investing.com - Investing.com Australia

Skye announces cohort review committee approved opening of cohort 2 based on favorable safety data from first four participants treated in cohort 1 - marketscreener.com

Skye Bioscience gets approval to open second cohort in study - Investing.com

Skye Announces Cohort Review Committee Approved Opening of Cohort 2 Based on Favorable Safety Data from First Four Participants Treated in Cohort 1 - The Manila Times

Skye Announces Cohort Review Committee Approved Opening of - GlobeNewswire

Skye Bioscience (SKYE) price target decreased by 11.48% to 7.87 - MSN

Skye Bioscience, Inc. (SKYE) Stock Live Price, Chart & News - CoinCodex

Skye Bioscience Faces Nasdaq Compliance Risk Over Equity - The Globe and Mail

[8-K] Skye Bioscience, Inc. Reports Material Event - Stock Titan

INSM

$112.84

1.17%

RPRX

$57.80

1.55%

ROIV

$36.31

2.60%

MRNA

$79.77

2.48%

ONC

$308.96

0.16%

RVMD

$190.46

0.25%

Apri su Yahoo | Apri su Google | Aperto in Finviz | Apri in MarketWatch | Aperto a EDGAR | Aperto su Reuters